Are There Effective Psychopharmacologic Treatments for PTSD?

Teddy J. Akiki, Chadi G. AbdallahThe Journal of Clinical Psychiatry 2018 · DOI

Abstract

Posttraumatic stress disorder (PTSD) is a common and debilitating condition that develops in certain individuals after exposure to traumatic events, with a lifetime prevalence of 6.4% in the United States. PTSD is typically characterized by a chronic and often severe time course, with a substantial symptom burden and rate of disability. PTSD symptomatology is multifaceted, with symptom dimensions that include re-experiencing, avoidance of trauma-related stimuli, negative thoughts and feelings, and arousal and reactivity.

Introduction

Despite the prevalence of PTSD, pharmacological options remain surprisingly sparse. Currently, only two medications—paroxetine and sertraline (both SSRIs)—are FDA-approved for the treatment of PTSD. This clinical review addresses the "suboptimal response" observed with current treatments, where many patients fail to achieve remission and therapeutic effects often take weeks to manifest. Consequently, clinicians frequently resort to off-label prescriptions, such as antipsychotics or sleep aids, despite a lack of robust evidence supporting their efficacy. This paper synthesizes current evidence to guide clinicians through these limited options while exploring the next generation of precision-based treatments.

Review Methodology

This article provides a clinical review and expert commentary, synthesizing findings from various sources:

  • Meta-analyses and Randomized Controlled Trials (RCTs): Evaluation of SSRIs, SNRIs, and atypical antidepressants.
  • Clinical Guidelines: Comparison of recommendations from the VA/DoD, the American Psychiatric Association (APA), and the International Society for Traumatic Stress Studies (ISTSS).
  • Large-Scale Trials: Analysis of discrepancies in findings for drugs like prazosin and risperidone, including the Raskind et al. (2018) trial in veterans and the Krystal et al. (2011) trial on risperidone augmentation.

Key Insights and Clinical Evidence

The Efficacy of Standard Pharmacotherapy

Current first-line treatments, primarily SSRIs and SNRIs, show modest clinical effectiveness. Less than 60% of patients achieve a meaningful clinical response, and remission rates are notably low, ranging between 20% and 30%. While trauma-focused psychotherapies appear at least as effective as pharmacotherapy, challenges such as patient "buy-in" and high dropout rates persist.

The "Prazosin Paradox" and Precision Medicine

Prazosin, an $\alpha_1$-adrenoreceptor antagonist, showed significant promise in early, small-scale trials for treating nightmares and sleep disturbances. However, a recent large-scale trial (n > 700) found no significant difference from placebo. The authors suggest this discrepancy may stem from selection bias, where the large trial included clinically stable patients, potentially excluding those most likely to benefit. Interestingly, high baseline blood pressure has been identified as a potential predictor for prazosin response, highlighting the need for "biotypes" to match patients with specific treatments.

Risks of Benzodiazepines and Adjunctive Therapies

Despite common use for hyperarousal, benzodiazepines show no measurable benefit in PTSD. Evidence suggests they may worsen outcomes, increase the risk of developing PTSD post-trauma, and interfere with the efficacy of psychotherapy. Similarly, a large RCT investigating risperidone as an adjunct to SSRI therapy showed no benefit over placebo, although quetiapine monotherapy has shown some potential.

The Shift Toward Rapid-Acting Agents

A significant limitation of traditional antidepressants is their slow onset of action. Emerging research into N-methyl-D-aspartate (NMDA) receptor modulators, such as ketamine, and MDMA-augmented psychotherapy represents a promising frontier. These agents may offer faster and more sustained relief by targeting different neurobiological pathways.

Limitations and Future Directions

The primary challenge in PTSD treatment is the lack of biological specificity. Most current medications were originally developed for depression or anxiety rather than the specific neurobiology of PTSD, which involves synaptic dysregulation and inflammatory pathways.

Future research should focus on: 1. Biomarker Discovery: Transitioning from symptom-based diagnosis to biological "biotypes" to predict treatment response. 2. Synergistic Treatments: Investigating the potential for combining pharmacotherapy with psychotherapy to create enhanced therapeutic effects. 3. Novel Pathways: Further exploration of the noradrenergic system and rapid-acting glutamatergic modulators.

Summary updated

Abstract

Article Abstract Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text. Posttraumatic stress disorder (PTSD) is a common and debilitating condition that develops in certain individuals after exposure to traumatic events, with a lifetime prevalence of 6.4% in the United States. PTSD is typically characterized by a chronic and often severe time course, with a substantial symptom burden and rate of disability. PTSD symptomatology is multifaceted, with symptom dimensions that include re-experiencing, avoidance of trauma-related stimuli, negative thoughts and feelings, and arousal and reactivity.
BibTeX
@article{akiki2018are,
  author = {Teddy J. Akiki and Chadi G. Abdallah},
  title = {{Are There Effective Psychopharmacologic Treatments for PTSD?}},
  journal = {The Journal of Clinical Psychiatry},
  year = {2018},
  doi = {10.4088/jcp.18ac12473},
}
Figure